UNSPSC 51313302: Thiazinam or thiazinamium

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 666W2P28N2, chemically known as 10h-phenothiazine-10-ethanaminium, n,n,n,alpha-tetramethyl-, methyl sulfate but generally known as thiazinamium, which bears US NIH Compound Identifier 6015. European Medicines Agency schedules Thiazinamium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15532MIG.

As of Q4 2014, THIAZINAMIUM remains the US FDA Preferred Term for this commodity. Thiazinamium bears US NLM identifiers UMLS ID C0039857 and NCI Concept Code C84203. SMILES: S1C2C(N(CC([N](C)(C)C)C)C3C1CCCC3)CCCC2.S(=O)(=O)(OC)O.

UNSPSC 51313302 Thiazinam or thiazinamium is a Commodity code that in practice does not align with recent state and local procurement activity. The three most recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceuticals and OTC products—none of which falls within the thiazinam therapeutic class. The code appears to be a misapplication by the issuing bodies rather than a reflection of actual thiazinam demand in state and local markets.

The opportunities that are tagged under this code span different issuing bodies and procurement mechanisms. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023) seeking naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across multiple state and local government facilities in Minnesota and Oregon. The mismatch between the code name and the actual procurement scope suggests that state and local agencies are either applying a generic pharmaceutical commodity code or that the underlying data reflects a cataloging error rather than genuine market demand for thiazinam specifically.